FRANKLIN LAKES, N.J., Jan. 15, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that the U.S.

U.S. judge finds BD's devices do not violate Baxter's drug reconstitution patents BD still facing separate Baxter patent case over medical-infusion pumps (Reuters) - Becton, Dickinson & Co convinced a ...

Leading medical technology firm Becton, Dickinson and Company (BDX) recently revealed that its segment BD Medical received FDA clearance for its BD PhaSeal Closed System Transfer Device as per the ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it signed a definitive agreement to acquire Carmel Pharma, Inc., a Swedish company ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of its acquisition of Carmel Pharma, AB, a Swedish company that manufactures ...

, a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the BD PhaSeal™ Closed System Transfer Device (CSTD) under the newly created ...

FRANKLIN LAKES, N.J. — Becton, Dickinson and Co. now owns the manufacturer of the PhaSeal system. BD said it has completed its acquisition of Sweden-based Carmel Pharma. Through the deal, BD now owns ...

) announced today that it signed a definitive agreement to acquire Carmel Pharma, Inc., a Swedish company that manufactures the PhaSeal® System, the leading closed-system drug transfer device for the ...

GÖTEBORG, Sweden--(BUSINESS WIRE)--The majority shareholders of Carmel Pharma AB ("Carmel") have entered into an agreement with BD (Becton, Dickinson and Company) to sell approximately 95% of the ...

Leading medical technology firm Becton, Dickinson and Company ( BDX) recently revealed that its segment BD Medical received FDA clearance for its BD PhaSeal Closed System Transfer Device as per the ...